Stock AFFYMAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Affymax, Inc. Stock OTC Bulletin Board

Equities

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Affymax, Inc.
2014 Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer CI
2014 Affymax Seeks Acquisitions CI

Financials (USD)

Sales 2012 94.37M Sales 2013 1.37M Capitalization 29.24M
Net income 2012 -93M Net income 2013 -14M EV / Sales 2012 6.75 x
Net cash position 2012 69.14M Net cash position 2013 5.6M EV / Sales 2013 17.3 x
P/E ratio 2012
-7.39 x
P/E ratio 2013
-2.03 x
Employees -
Yield 2012 *
-
Yield 2013
-
Free-Float 100%
More Fundamentals * Assessed data

Latest news about Affymax, Inc.

Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer CI
Affymax Seeks Acquisitions CI
Affymax, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014 CI
Affymax Terminates Omontys' Product Collaboration and License Agreement with Takeda Pharmaceutical Company, Effective September 10, 2014 CI
Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement CI
Affymax To Review Strategic Options CI
Affymax, Inc. Auditor Raises 'Going Concern' Doubt CI
Affymax, Inc. Executes a Seventh Amendment to Lease Agreement CI
Affymax, Inc. Announces Management Changes CI
Affymax, Inc.(OTCPK:AFFY) dropped from NASDAQ Composite Index CI
Affymax, Inc.(OTCPK:AFFY) dropped from NASDAQ Biotechnology Index CI
Affymax, Inc. to Terminate John Orwin as Chief Executive Officer After May 15, 2013 CI
Affymax, Inc. to Reduce Workforce Amid Product Investigation CI
Affymax, Inc. Enters into a Letter Agreement with Oxford Finance Corporation and Silicon Valley Bank CI
Affymax, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012 CI
More news

Company Profile

Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AFFY Stock
  4. Stock